GOSS vs. HRTX, IGMS, AVTE, CMPS, CYRX, CDMO, MREO, APLT, ALT, and ATXS
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Heron Therapeutics (HRTX), IGM Biosciences (IGMS), Aerovate Therapeutics (AVTE), COMPASS Pathways (CMPS), Cryoport (CYRX), Avid Bioservices (CDMO), Mereo BioPharma Group (MREO), Applied Therapeutics (APLT), Altimmune (ALT), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Gossamer Bio (NASDAQ:GOSS) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.
Heron Therapeutics has higher revenue and earnings than Gossamer Bio. Heron Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Heron Therapeutics received 512 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 69.01% of users gave Heron Therapeutics an outperform vote while only 65.32% of users gave Gossamer Bio an outperform vote.
In the previous week, Heron Therapeutics had 7 more articles in the media than Gossamer Bio. MarketBeat recorded 9 mentions for Heron Therapeutics and 2 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.52 beat Heron Therapeutics' score of 0.66 indicating that Gossamer Bio is being referred to more favorably in the media.
Gossamer Bio has a net margin of 0.00% compared to Heron Therapeutics' net margin of -61.28%. Heron Therapeutics' return on equity of 0.00% beat Gossamer Bio's return on equity.
Gossamer Bio currently has a consensus price target of $7.65, suggesting a potential upside of 1,196.61%. Heron Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 48.65%. Given Gossamer Bio's higher probable upside, equities research analysts clearly believe Gossamer Bio is more favorable than Heron Therapeutics.
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by insiders. Comparatively, 6.4% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Gossamer Bio has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.
Summary
Heron Therapeutics beats Gossamer Bio on 10 of the 17 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
